Immuron Limited (AU:IMC) has released an update.
Immuron Limited is set to advance their drug IMM-529, targeting the prevention and treatment of Clostridioides difficile infection (CDI), into a Phase 2 trial after positive feedback from the FDA, with an IND application expected in the first half of 2025. The treatment aims to reduce reliance on antibiotics by using antibodies to clear infections and restore gut flora, offering a potential breakthrough in combating antibiotic-resistant ‘superbugs.’ Market analysis suggests significant revenue potential for IMM-529, especially if used early in CDI treatment protocols.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
